SRDX icon

Surmodics

39.75 USD
-0.16
0.40%
At close Dec 20, 4:00 PM EST
After hours
39.75
+0.00
0.00%
1 day
-0.40%
5 days
-0.53%
1 month
1.48%
3 months
1.25%
6 months
-5.24%
Year to date
11.78%
1 year
11.66%
5 years
-4.42%
10 years
81.92%
 

About: Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

Employees: 389

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

18% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 33

12% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 26

2% more funds holding

Funds holding: 123 [Q2] → 126 (+3) [Q3]

17.39% less ownership

Funds ownership: 100.56% [Q2] → 83.17% (-17.39%) [Q3]

24% less capital invested

Capital invested by funds: $603M [Q2] → $457M (-$146M) [Q3]

74% less call options, than puts

Call options by funds: $135K | Put options by funds: $527K

75% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 1 (-3) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for SRDX.

Financial journalist opinion

Positive
Zacks Investment Research
1 week ago
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?
Positive
Zacks Investment Research
1 month ago
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
Positive
Zacks Investment Research
1 month ago
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
Negative
Zacks Investment Research
1 month ago
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
Neutral
Business Wire
1 month ago
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”) license fee revenue(1) of $31.3 million, an increase of 1.
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Neutral
Business Wire
1 month ago
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce™.
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
Neutral
Zacks Investment Research
2 months ago
SRDX Stock Down Despite FDA Clearance for Pounce XL System
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SRDX Stock Down Despite FDA Clearance for Pounce XL System
Neutral
Business Wire
2 months ago
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System is indicated for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature in vessels 5.5–10 mm in diameter, making it suitable for iliac, femoral, and other art.
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
Positive
Zacks Investment Research
3 months ago
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Positive
Zacks Investment Research
3 months ago
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
Charts implemented using Lightweight Charts™